News
UK government to invest £10m in new breast cancer screening units
The government has pledged £10m to speed up breast cancer diagnosis and treatment

The UK government has announced a £10m investment to develop 29 new breast cancer screening units.
The units will be directed to areas where they are most needed to increase capacity and speed up diagnosis and treatment.
The announcement follows concerns voiced by the charity Breast Cancer Now over a decline in breast cancer early-stage diagnosis as a result of the pandemic.
The data has shown a dip in the rate of early, stage one and two, breast cancer diagnosis – a sharp contrast to the years leading up to the pandemic when early diagnosis rates were rising.
The government’s latest investment is hoped to reverse the trend, allowing more women to be screened earlier and access care closer to home.
“Last year 100,000 people were diagnosed with cancer at stages one and two. This is the highest proportion on record but we want to do better still,” said Minister of State for Health, Helen Whately.
“These breast cancer screening units will mean more people can get checked for cancer, closer to home.
“Most people will get the reassurance of an all-clear but for those who are diagnosed, catching their cancer early is the best thing we can do.”
As part of the investment, the government will provide 16 new mobile breast screening units, 13 static units, 58 live remote access upgrades for existing units and 10 software upgrades in areas with existing units to carry out ultrasounds and X-rays.
The funding is now in place for NHS trusts to spend within the 2022 to 2023 financial year and the timing for delivery of units will be individual to each trust.
Steve Russell, NHS national director for screening and vaccinations, said: “Screening is vital in detecting breast cancer early and getting better outcomes for patients, and this further investment is great news for improving access to breast screening services for women across England.
“This funding will help increase screening rates among women from communities and regions where uptake is lowest by improving facilities in both fixed and mobile locations, making it easier for more women to get checked, and we encourage anyone invited for a screening to take up their appointment without delay and help us catch cancers earlier when they are easier to treat.”
Ciarán Norris, head of campaigns and public affairs at Macmillan Cancer Support, said: “We welcome any intervention that helps to speed up diagnosis and improve access to cancer screening services, particularly in areas where they are most needed, as we know the earlier someone is diagnosed the better their outcome is likely to be.
“Alongside this, we also look forward to working with the government on steps to grow and sustain the cancer workforce, to ensure our cancer services can provide timely treatment and care for everyone living with cancer, both now and in the future.”
Breast screening is one of the best ways to spot a cancer that is too small to feel or see. Each year more than two million women have breast cancer screening in the UK through the NHS Breast Screening Programme.
Entrepreneur
WHIS 2026 adds 18 new speakers to October summit agenda

The Women’s Health Innovation Summit (WHIS), the event uniting the global women’s health ecosystem, has just announced 18 new speakers joining the agenda for its 2026 summit, taking place October 13–15 at Encore Boston Harbor.
The latest additions bring further depth across pharma, clinical research, health systems, venture, and policy, reinforcing WHIS’s role as the only platform where the full women’s health ecosystem convenes under one roof.
Newly confirmed speakers include:
- Kelle Moley, MD – VP, Women’s Health Early Phase Clinical Development, Cardiometabolic Research, Eli Lilly & Company
- Justine Levin-Allerhand – Executive Partner, Chief Corporate Development Officer & COO, Flagship Labs, Flagship Pioneering
- Sebnem Yildirimoglu, MD, PMP – Executive Director, Women’s Health Strategy, Premier Research
- Terri Stewart – Head of Global Healthcare & Government Affairs, EMD Serono
- Dr. Morag Grassie – Executive Director, Blavatnik Fund for Innovation, Yale
- Sandra Butler – Director, Design Impact, Mass General Brigham
- Zhenya Lindgardt – Chief Executive Officer, Sera Prognostics
- Sadie Morahan – Head of US Revenue, Withings Health Solutions
- Angela Drew, PhD – Vice President, Regulatory Strategy, Premier Research
- Dr. Stephanie Lahr – CMIO, Aqurio
- Michelle Andrews – Contributing Writer, KFF Health News
- Charlotte Williams – CEO, My Bump Hub
- Clint Dart, MS – Director, NIH Women’s Health Data Coordinating Center, Premier Research
- Cass Sanford – US Venture Advisor, FemTech Lab
- Megan Mukuria – Founder & CEO, ZanaAfrica
- Tiffany Inglis, MD, FACOG – Chief Medical Officer, Sera Prognostics
- Angelean Hendrix, PhD – Vice President, Pharmacometrics and MIDD, Premier Research
- Amanda Ducach – CEO & Co-founder, EmaEQ
“WHIS is where the women’s health industry comes together to take action,” said Poppy Howard-Wall, Event Director at WHIS.
“This latest wave of speakers reflects exactly the kind of cross-sector expertise our attendees expect – from global pharma and clinical research leadership to venture, health systems, and grassroots innovation.
“It’s this breadth that makes WHIS the room where things actually move forward.”
Bringing the Full Ecosystem Together
These additions join a growing 2026 agenda spanning four content tracks that reflect the full lifecycle of healthcare innovation, from early-stage research and development through to patient delivery, system transformation, and commercial scale.
Attendees can expect over 1,000 senior decision-makers, 120+ expert speakers, four dedicated stages, and more than 10 hours of curated 1:1 meetings.
Full speaker and agenda details are available at whisusa.com/speakers-2026.
About WHIS
The Women’s Health Innovation Summit is the only platform uniting the full women’s health ecosystem – providers, payers, employers, pharma leaders, investors, and innovators -to increase deal flow, expand reimbursement, improve access, and deliver better outcomes for women at every stage of life.
Diagnosis
Millions in England to be offered ‘gamechanging’ home testing kits for cervical cancer
Menopause
Quarter of women miss work due to menstual symptoms, survey finds

Nearly a quarter of women often miss work because of menstrual symptoms, according to a survey examining hormonal health among women in full-time work in Ireland.
The survey looked at the impact of menstruation, fertility and motherhood, and perimenopause and menopause.
Research from The Menopause Hub found more than one in three women who had not disclosed a menstrual health issue at work said the lack of a clear workplace policy was the reason.
More than a quarter said they did not think their concerns would be taken seriously, while 22 per cent cited embarrassment and 18 per cent feared being judged.
Nearly half of respondents said better workplace support would have made them feel less stressed, while 40 per cent said it would have made them feel more valued. Some 36 per cent said they would have felt more comfortable speaking up.
Some 76 per cent of women surveyed said they experienced menstrual health issues, with 23 per cent of those often missing work because of symptoms.
Nearly half of respondents, 49 per cent, said they felt uncomfortable talking about menstruation at work.
One respondent said: “As a woman, we try to get through the day, sometimes in pain that can’t be seen. We feel emotionally and physically drained.”
The research also found that 62 per cent of those who experienced baby loss reported a moderate or significant impact on work attendance.
More than half of respondents who experienced depression during pregnancy also reported a moderate or significant impact on attendance.
Some 63 per cent of mothers said it was “difficult” to return to work after pregnancy, while nearly half said their maternity pay arrangement had negatively affected their financial wellbeing.
One respondent said: “I almost walked away. The only reason I stayed was because I had to provide for my family.”
The survey also found that nearly half of respondents said menopause had some impact on their attendance, while more than six in 10 reported an impact on their work performance.
Some 44 per cent of women said they were “uncomfortable” discussing perimenopause and menopause at work.
One person said they were “already terrified of losing my job at my age:
“I need to just struggle through this without support or acknowledgement. That’s basically workplace discrimination.”
The Menopause Hub chief executive Loretta Dignam said women’s hormonal health has been treated as a “private or personal issue” for too long, “when the reality is that it has a very real impact on women’s working lives”.
“The fundamental point is that women are not ‘mini men.’
“Our biology is different, and workplaces that were largely designed around a male model of health and working life need to evolve to recognise that.
“What is striking is how many women continue to show up, perform, push through and progress at work while managing significant physical and emotional symptoms, often without the policies, understanding or practical support they need,” Dignam said.
She added that because expectations are changing, Gen Z and Gen Alpha employees will be “far less willing than previous generations to accept workplaces that ignore their health and wellbeing”.
Entrepreneur2 weeks agoApplications close August 18 for Women’s Health Innovation Summit 2026 Innovation Showcase
Menopause2 weeks agoThird of women unaware of perimenopause mental health impact
Fertility1 week agoChelsea FC Women to launch first-of-its-kind player fertility fund
Menopause2 weeks agoMenopausal hormone therapy may lower dementia risk, study suggests
Opinion1 week agoanna perimenopause app launches across 39 markets
Hormonal health2 weeks agoWe are wrapping our children in plastic and calling it care
Pregnancy2 weeks agoChemicals in plastics may be linked to high blood pressure during pregnancy
News2 weeks agoWomen with endometriosis face 46% higher risk of type 2 diabetes – study














Pingback: AI to check breast cancer scans in groundbreaking NHS trial - FemTech World